SIRPα Cancer Immunology Research
Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Search
New data for nintedanib in children with fibrosing ILD
InPedILD Phase III trail showed encouraging results for both primary end points. If approved, nintedanib would become the first approved treatment for pediatric patients with fibrosis ILD.
Patient voices Augustos story
Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Patient voices Eves story
Eve’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Patient voices Ulrichs story
Ulrich’s Story: Hear from patients and families on how atrial fibrillation (AF), deep vein thrombosis (DVT) and pulmonary embolism (PE) have affected their lives
Boehringer Ingelheim - Life Forward
Learn how we change life for the better for people and animals.
Full data chronic kidney disease trial efficacy
Positive full data results announced from the EMPA-KIDNEY Phase III trial in adults with chronic kidney disease
cat dog flea allergy dermatitis
Find out how you can identify and treat flea allergy dermatitis, one of the most common illnesses associated with a flea infestation.
Spesolimab meets key endpoint for GPP flare prevention
Spesolimab meets primary and key secondary endpoint for prevention of generalized pustular psoriasis flares
Biostatistics & Data Science
Discover how we use data science methods on clinical trials data to develop patient-led innovations and breakthrough treatments.
Telling my story AF and DVT PE Patient Voices
Central Data Science
Together with our business and IT colleagues, we develop data science-driven solutions, all the way from ideation to product.
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Global Computational Biology & Digital Sciences
Discover how we play a vital role in identifying new drugs and how our work results in breakthrough therapies.
Patient Voices...Ian's Story
2020-Positive-business-momentum-despite-COVID-19-impact
While stepping up its investments in R&D significantly, Boehringer Ingelheim achieved a solid business performance in 2020 despite the COVID-19 pandemic.
The liver and its vital connection to our overall health
How health of the liver impacts our interconnected cardiovascular, renal, metabolic system and suffering and can have several comorbidities like obesity.
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Conversations Beyond Type 2 Diabetes
Anne and Franc, who are living with T2D, explore what it means to live with their condition and its associated comorbidities.
Groundbreaking oncology research zongertinib
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
Mareks Disease Poultry Chicken
Five things you need to know to keep poultry free from outcomes of one of the most common virus affecting the animals’ immune systems.
EURORDIS Award
EURORDIS has selected Boehringer Ingelheim for the first time as recipient of the prestigious Black Pearl Award 2020